Neurological aspects of COVID-19

The novel coronavirus pandemic presents one of the most significant challenges to modern healthcare, which involves all medical specialties. The current review encompasses the neurologic manifestations of COVID-19 - a yet to be defined problem. L. Mao et al. (2020) have found a third of COVID-19 patients to exhibit neurological symptoms the latter divided into three categories: Central nervous system involvement (vertigo, headache, altered consciousness, acute cerebrovascular pathology, ataxia, and seizures) in 24.8% of patients, peripheral nervous system involvement (smell and taste disorders, neuropathy) - 8.9%, and muscle pathology (muscle pain, associated with creatine kinase increase) - 10,7%. Cerebrovascular pathology in 221 patients, described by Y. Li et al. (2020) occurred in 5.9% of cases - the majority was comprised by ischemic stroke, and as a whole it was associated with a more severe disease course. T. Oxley et al. (2020) described 5 patients (less than 50 years of age) with a large-vessel stroke occurring as a result of COVID-19. It has been shown that meningoencephalitis may be linked to COVID-19 - this review addresses several described cases. A case series of Guillain-Barré syndrome n patients with SARS-CoV-2 infection is also described. Apart from that, it is well established that COVID-19 may lead to deterioration of concurrent somatic and (or) neurological diseases, worsening the prognosis